Antonio Llombart‐Cussac

MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy

George W. Sledge, Masakazu Toi, Patrick Neven et al. · Journal of Clinical Oncology · 2017 · 1.7K citations · Full text

Medicine, Oncology, Pharmacotherapy +17

The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2

George W. Sledge, Masakazu Toi, Patrick Neven et al. · JAMA Oncology · 2019 · 987 citations · Full text

Medicine, Oncology, Pharmacology +17

Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study

W. Eiermann, Stefan Paepke, Justus Appfelstaedt et al. · Annals of Oncology · 2001 · 716 citations

Medicine, Oncology, Pharmacotherapy +10

Relationship Between Quantitative Estrogen and Progesterone Receptor Expression and Human Epidermal Growth Factor Receptor 2 (HER-2) Status With Recurrence in the Arimidex, Tamoxifen, Alone or in Combination Trial

Mitch Dowsett, Craig Allred, Jill Knox et al. · Journal of Clinical Oncology · 2008 · 465 citations

Medicine, Endocrinology, Oncology +17

Gemcitabine Plus Paclitaxel Versus Paclitaxel Monotherapy in Patients With Metastatic Breast Cancer and Prior Anthracycline Treatment

Kathy S. Albain, Shona Nag, G. Calderillo-Ruiz et al. · Journal of Clinical Oncology · 2008 · 422 citations · Full text

Medicine, Oncology, Pharmacology +17